Atjaunināt sīkdatņu piekrišanu

Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis 1996 ed. [Hardback]

Edited by , Edited by , Edited by , Edited by
  • Formāts: Hardback, 240 pages, weight: 544 g, 240 p., 1 Hardback
  • Sērija : Developments in Cardiovascular Medicine 180
  • Izdošanas datums: 29-Feb-1996
  • Izdevniecība: Springer
  • ISBN-10: 0792338073
  • ISBN-13: 9780792338079
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 73,64 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Standarta cena: 86,65 €
  • Ietaupiet 15%
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis 1996 ed.
  • Formāts: Hardback, 240 pages, weight: 544 g, 240 p., 1 Hardback
  • Sērija : Developments in Cardiovascular Medicine 180
  • Izdošanas datums: 29-Feb-1996
  • Izdevniecība: Springer
  • ISBN-10: 0792338073
  • ISBN-13: 9780792338079
Citas grāmatas par šo tēmu:
A unique overview of all major angiographic lipid intervention trials, presented by their principal investigators. Basic mechanisms and methodological aspects, including biochemical as well as angiographic aspects, are discussed by experts in these fields. A careful comparison of all available data permits an analysis to be made of what may currently be considered proved, which aspects merit further investigation, and which hypotheses should be rejected.
Audience: Clinicians involved in the practice of lipid lowering and investigators involved in lipid-lowering clinical trials. Scientists involved in other areas of lipid research and investigators conducting coronary angiographic trials designed to study the influence of different interventions will find a wealth of information and practical guidelines in this book.
One: Mechanisms of progression and regression.-
1. Role of lipoproteins
in progression of coronary arteriosclerosis.-
2. Pathophysiological basis for
lipid intervention trials.- Two: Methodological aspects of angiographic
trials.-
3. The use of metabolic measurements in angiographic regression
trials.-
4. Quality control in quantitative coronary arteriography.-
5. Is
there a place for visual assessment?.-
6. Angiographic endpoints in
progression trials.- Three: Angiographic lipid lowering clinical trials.-
7.The Cholesterol Lowering Atherosclerosis Study (CLAS).-
8. Clinical
efficacy and safety of pravastatin treatment in symptomatic patients the
REGRESS trial.-
9. Familial Atherosclerosis Treatment Study.-
10. Pravastatin
Limitation of Atherosclerosis in the Coronary Arteries (PLAC 1): a summary.-
11. The Multicenter Anti-Atheroma Study (MAAS).-
12. Lessons from the
Monitored Atherosclerosis Regression Study (MARS) and beyond: atherosclerosis
progression/regression responses to therapy depend on lesion size and
composition.-
13. The St Thomas Atherosclerosis Regression Study and an
appraisal of its potential limitations.-
14. Effects of the lipid
intervention in the Stanford Coronary Risk Intervention Project.-
15.
Canadian coronary atherosclerosis study on the effect of lovastatin on the
progression of coronary artery disease (CCAIT): why are results different?.-
16. Impact upon angiographic disease progression following step drug therapy
in normolipidaemic patients: results of the Harvard Atherosclerosis
Reversibility Project (HARP).-
17. Effect of aggressive versus conventional
lipid-lowering treatment on coronary and peripheral atherosclerosis: design
and baseline characteristics of the LDL-Apheresis Atherosclerosis Regression
Study (LAARS).-
18. The NHLBIPost-Coronary Artery Bypass Graft Clinical Trial
(Post-CABG): angiographic outcomes.- Epilogue.